ERBB4 E934K
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ERBB4
Variant E934K
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ERBB4 E934K lies within the protein kinase domain of the Erbb4 protein (UniProt.org). E934K has been identified in sequencing studies (PMID: 26933808, PMID: 26010451, PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Apr 2026).
Associated Drug Resistance
Category Variants Paths

ERBB4 mutant ERBB4 E934K

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005235.3
gDNA chr2:g.211424221C>T
cDNA c.2800G>A
Protein p.E934K
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001042599 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38
NM_005235 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38
NM_005235.2 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38
NM_001042599.1 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38
NM_001042599.1 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38
NM_005235.3 chr2:g.211424221C>T c.2800G>A p.E934K RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB4 mutant lung squamous cell carcinoma predicted - sensitive Afatinib Phase III Actionable In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB4 (HER4) mutations predicted an OS (HR=0.22) and PFS (HR=0.21) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587). 29902295